Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06093152
Other study ID # 223/2021
Secondary ID FIMEA/2023/00395
Status Recruiting
Phase
First received
Last updated
Start date October 23, 2023
Est. completion date December 2025

Study information

Verified date January 2024
Source University of Oulu
Contact Ville Lindholm, MD
Phone +35883155283
Email Ville.a.lindholm@oulu.fi
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The study is video assisted cross-over study evaluating the effect of inhaled salbutamol in wheeze in children 6-24 months old.


Description:

The object of the study is to evaluate the effect of inhaled salbutamol in wheeze in children 6-24 months old. In despite of the lack of evidence of salbutamol, it is considered the gold standard in acute wheezing. Placebo-controlled study would be unethical so all participants are treated with salbutamol based on current guidelines. Instead, participants serve as control subjects of their own which is executed by a type video assisted cross-over study. Participants are filmed before and after the treatment. Afterwards a panel of pediatricians not participating in the treatment of the participants independently evaluates the difficulty of the wheeze. Videos are randomly arranged and members of the panel are blinded to the time point (before/after) of videos. In addition, collected videos are analyzed using machine vision. Biosignals are collected from the videos and evaluated using algorithms in order to show that machine vision can be utilized to evaluate the difficulty of wheezing. The machine vision analysis is compared to the evaluation of the panel of pediatricians.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 6 Months to 24 Months
Eligibility Inclusion Criteria: - Wheezing - Salbutamol-treatment in emergency department prescribed Exclusion Criteria: - Need for immediate resuscitation - Immediate transfer to ICU - Suspicion of pneumonia based on the auscultation finding - Suspicion of airway foreign body

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Salbutamol
Inhaled salbutamol (SABA, selective beta2-adrenergic receptor agonist) 0,1 mg 4-6 puffs 3-4 times every 20 minutes administered by OptiChamber holding chamber.

Locations

Country Name City State
Finland Department of Pediatrics, Oulu University Hospital Oulu

Sponsors (1)

Lead Sponsor Collaborator
University of Oulu

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in modified RDAI RDAI = Respiratory Distress Assessment Instrument, modified to not include auscultation findings. Range 0-18. Higher score indicates more difficult respiratory distress. Evaluated by the blinded panel afterwards using collected videos. Videos collected immediately before and after the intervention. Within 3 hours of study entry
Secondary Change in saturation of peripheral oxygen Change in saturation measured immediately before and after the intervention. Within 3 hours of study entry
Secondary Change in auscultation finding Evaluated by review of medical records (i.e. based on the findings of the physician treating the patient). Assessed as difficult (wheezing lasting all expiration and possibly inspiration in all 4 lung fields), medium (no inspiratory wheezing, lasting all expiratory OR in all lung 4 fields) of mild (no inspiratory wheezing, wheezing not lasting all expiratory and not in all lung fields). Assessed immediately before and after the intervention. Within 3 hours of study entry
Secondary Change in the difficulty of the respiratory distress Subjective evaluation of the respiratory distress based on the appearance of the patient on the video. Range 0-10, higher score indicating more difficult respiratory distress. Assessed by the blinded panel afterwards using videos collected immediately before and after the intervention. Within 3 hours of study entry
Secondary Machine-vision assisted analysis of respiratory status Machine vision analysis of the difficulty of wheezing (none - mild - difficult). Assessed using videos collected immediately before and after the intervention. Within 3 hours of study entry
See also
  Status Clinical Trial Phase
Recruiting NCT04669288 - AZithromycin Therapy in Preschoolers With a Severe Wheezing Episode Diagnosed at the Emergency Department Phase 3
Withdrawn NCT04584034 - Bronchodilators for Wheeze in Young Children Presenting to Primary Care: a Randomised, Placebo-controlled, Multicentre, Parallel Group Trial Phase 4
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Enrolling by invitation NCT00775697 - Montelukast in Children With Wheezing Phase 4
Completed NCT00749528 - Evaluation of Toxic Metals, Trace Elements and Total Antioxidant Activity in Children With Recurrent Wheezing N/A
Recruiting NCT00494624 - Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Phase 4
Recruiting NCT04128592 - Non-invasive Differential Diagnosis of Noisy Breathing Infants and Toddlers N/A
Completed NCT01452945 - Bedside Lung Ultrasound in Young Children Presenting to the Emergency Department (ED) With Wheezing N/A
Withdrawn NCT00628303 - A Phase 3 Trial of the Effect of Motavizumab Prophylaxis on Reduction of Serious Early Childhood Wheezing in Infants Phase 3
Completed NCT01028560 - Allergy Immunotherapy for the Reduction of Asthma Phase 1/Phase 2
Completed NCT00626808 - A Post Marketing Evaluation of the Effectiveness of FluMist Risk Minimization Plan in Children Phase 4
Completed NCT00507676 - Lung Function and Structure in Healthy Infants and Infants With Recurrent Wheezing N/A
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Recruiting NCT06106646 - Vitamin C to Decrease Effects of Smoking in Pregnancy on Infant Lung Function (VCSIP) Longer Term Follow Up
Recruiting NCT05710081 - Bacterial Lysate In Preventing Asthma Phase 3
Completed NCT04011709 - A Methodology Trial Using the VR647 Inhalation System in Pediatric Subjects Who Have Previously Received Inhaled Therapy Early Phase 1
Active, not recruiting NCT03377192 - Impedance Pneumography in Assessment of Asthma Control in Preschool Children
Completed NCT01142505 - Wheeze and Intermittent Treatment Phase 3
Active, not recruiting NCT04942483 - Using Specific Tests in Preschool Children With Wheeze to Help us Determine the Necessity of Inhaled Corticosteroid Therapy (Feasibility Study).
Recruiting NCT05684848 - Evaluate the Effect of Nasal Spray in the Prevention of RTI in Children With Pre-school Wheezing N/A